Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799757 | 0.91 | ALDH1A1 (0.62) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1798292 | 0.81 | ALDH1A1 (0.48) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1800666 | 0.81 | HPGDS (0.63) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1799866 | 0.79 | HPGDS (0.61) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1801541 | 0.79 | HPGDS (0.53) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1798908 | 0.79 | ALDH1A1 (0.51) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL34467256 | 0.79 | CHEK2 (0.64) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1800987 | 0.78 | HPGDS (0.57) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2423459 | 0.78 | HPGDS (0.55) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1802043 | 0.77 | HPGDS (0.59) | ESR1ALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | PTGS1, PTGIS, PTGES | ESR1 563/4885ALDH1A1 368/4885HPGD 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.